Publicaciones en colaboración con investigadores/as de NewYork–Presbyterian Hospital (20)

2023

  1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  2. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

2022

  1. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

    The oncologist, Vol. 27, Núm. 7, pp. e561-e570

  2. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

    Nature communications, Vol. 13, Núm. 1, pp. 1878

2021

  1. An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients

    Critical Care, Vol. 25, Núm. 1

  2. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    Leukemia, Vol. 35, Núm. 3, pp. 835-849

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

  2. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine

  3. Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely

    Thrombosis Research, Vol. 189, pp. 61-68

2019

  1. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism (Internal and Emergency Medicine, (2019), 14, 7, (1101-1112), 10.1007/s11739-019-02077-5)

    Internal and Emergency Medicine

  2. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 3, pp. 420-435

  3. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism

    Internal and Emergency Medicine

2017

  1. Erratum: Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA). [World J Emerg Surg. 11, (2016) (33)] DOI: 10.1186/s13017-016-0089-y

    World Journal of Emergency Surgery

2016

  1. Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

    World Journal of Emergency Surgery, Vol. 11, Núm. 1

  2. Atypical hemolytic uremic syndrome (aHUS): Essential aspects of an accurate diagnosis

    Clinical Advances in Hematology and Oncology, Vol. 14, Núm. 11, pp. 2-15

2015

  1. HIF-1α and PFKFB3 mediate a tight relationship between proinflammatory activation and anerobic metabolism in atherosclerotic macrophages

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 35, Núm. 6, pp. 1463-1471

  2. Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 11, pp. 6725-6732

2007

  1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2005

  1. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

    Journal of Cardiac Failure, Vol. 11, Núm. 4, pp. 260-269

1986

  1. Antigen-specific, MHC nonrestricted T helper cell-induced B cell activation

    Journal of Experimental Medicine, Vol. 164, Núm. 5, pp. 1773-1778